Ipratropium

證據等級: L5

預測適應症: 10 個

Ipratropium: From Bronchospasm to Obstructive Lung Disease

One-Sentence Summary

Ipratropium (Atrovent®) is a well-established inhaled anticholinergic bronchodilator, globally used for bronchospasm associated with COPD and asthma, though it currently holds no approved registration in India. The TxGNN model predicts it may be effective for Obstructive Lung Disease — a prediction backed by multiple completed Phase 3 clinical trials and 20 publications, firmly anchoring this as confirmed clinical evidence rather than an exploratory hypothesis.

Quick Overview

Item	Content
Original Indication	No India (CDSCO) registration on record; globally established for bronchospasm / COPD
Predicted New Indication	Obstructive Lung Disease
TxGNN Prediction Score	99.97%
Evidence Level	L1
India Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Ipratropium is a synthetic quaternary derivative of atropine that competitively blocks muscarinic receptors on airway smooth muscle — particularly M3 receptors, which mediate acetylcholine-induced bronchoconstriction and mucus hypersecretion. It also suppresses M2 receptor-mediated negative feedback that would otherwise amplify cholinergic tone. Because it carries a quaternary ammonium charge, it is poorly absorbed from the airway surface, which means bronchodilation is achieved with minimal systemic anticholinergic side effects — a distinct advantage over earlier agents such as atropine itself.

Obstructive lung disease — encompassing COPD, chronic bronchitis, and emphysema — is characterized by heightened parasympathetic (vagal) tone driving persistent bronchoconstriction and excessive mucus production. Ipratropium directly addresses this core mechanism. The Lung Health Study (NCT00000568), one of the largest and longest COPD trials ever conducted, used ipratropium MDI as an active intervention in smokers with early pulmonary function decline, providing some of the highest-quality direct evidence for this drug-disease pair.

Globally, ipratropium is a cornerstone of COPD management and appears in widely used combination products such as Combivent® (ipratropium + albuterol) and Berodual® (ipratropium + fenoterol). Two Cochrane systematic reviews confirm its clinical efficacy relative to tiotropium in stable COPD, and multiple post-marketing surveillance programs have validated its real-world tolerability across thousands of patients. The TxGNN model’s top-ranked prediction of obstructive lung disease is not a novel hypothesis — it is a strong computational confirmation of decades of established clinical evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00000568	Phase 3	Completed	N/A	Lung Health Study (LHS I & III): ipratropium MDI used directly in smokers with early COPD; assessed long-term rate of FEV1 decline, cardiopulmonary morbidity and mortality — highest-grade direct evidence for ipratropium in obstructive lung disease
NCT02233894	N/A	Completed	526	Post-marketing surveillance of Atrovent® (ipratropium) inhalets in COPD; real-world tolerability and efficacy under daily practice conditions
NCT02238171	N/A	Completed	346	Second post-marketing surveillance of Atrovent® inhalets in COPD; further confirmation of real-world safety profile
NCT00274040	Phase 3	Completed	141	Double-blind, double-dummy comparison: tiotropium 18 mcg once daily vs Atrovent MDI 20 mcg qid in COPD — bronchodilator efficacy and safety head-to-head
NCT02172443	Phase 3	Completed	50	Confirmatory tiotropium vs Atrovent MDI comparison in COPD; additional PK/efficacy data
NCT00400153	Phase 3	Completed	1,480	Combivent Respimat (ipratropium 20 mcg/salbutamol 100 mcg) vs Combivent® MDI in COPD; non-inferiority on FEV1 AUC confirmed
NCT02236169	Phase 2	Completed	30	PK comparability of ipratropium HFA-134a vs Atrovent® CFC aerosol in COPD patients; supports HFA formulation bridge
NCT02260011	Phase 2	Completed	41	Single-dose crossover: bronchodilator efficacy and safety of ipratropium HFA vs Atrovent® CFC in COPD
NCT01691482	Phase 4	Completed	56	4-week crossover: daily lung function variation with albuterol and ipratropium alone vs in combination in COPD patients
NCT01019694	Phase 3	Completed	470	Long-term safety and patient acceptability of Combivent Respimat vs free combination of Atrovent HFA + albuterol HFA in COPD

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26391969	2015	Cochrane Systematic Review	Cochrane Database Syst Rev	Tiotropium superior to ipratropium on FEV1, SGRQ, and exacerbation rate in stable COPD; ipratropium remains a clinically validated treatment across multiple RCTs
24043433	2013	Cochrane Systematic Review	Cochrane Database Syst Rev	Earlier Cochrane update on tiotropium vs ipratropium; confirms ipratropium efficacy with a consistent safety profile in stable COPD
38457591	2024	RCT	Medicine	Probiotics combined with budesonide + ipratropium vs budesonide + ipratropium alone in COPD (n=118); combination improved lung function and gut microbiota profile
7813271	1995	RCT	Chest	Nonbronchodilator effects of pirbuterol vs ipratropium in COPD: compared gas exchange and distribution of ventilation, revealing distinct pharmacodynamic profiles
8181328	1994	RCT	Chest	COMBIVENT Inhalation Aerosol Study: ipratropium + albuterol combination superior to either agent alone in COPD over 85-day multicenter double-blind trial
20163324	2010	Review/Meta-analysis	Expert Opin Drug Metab Toxicol	Comprehensive review of albuterol, ipratropium, and combined therapy in COPD — mechanism, clinical efficacy, and safety summary
2977109	1988	Review	Clinical Pharmacy	Foundational pharmacology review: chemistry, PK, clinical efficacy, and dosing of ipratropium in obstructive lung disease
28461224	2017	Clinical Study	EBioMedicine	Sex-related differences in FEV1 response to ipratropium in mild-to-moderate COPD; both male and female patients demonstrate clinically meaningful bronchodilator response
15257628	2004	Review	Drugs	Review of ipratropium/fenoterol (Berodual) delivered via Respimat Soft Mist Inhaler in asthma and COPD; device comparison and clinical outcomes
35616126	2022	Cochrane Systematic Review	Cochrane Database Syst Rev	Magnesium sulfate as adjunct in COPD exacerbations; contextualises ipratropium’s role within the wider AECOPD standard-of-care treatment landscape

India Market Information

Ipratropium currently has no registered products in India according to regulatory records in this dataset. The drug is not marketed in India (CDSCO) at this time.

Ipratropium is, however, globally approved and marketed under brand names including Atrovent® (Boehringer Ingelheim) and combination products such as Combivent® (ipratropium + albuterol) and Berodual® (ipratropium + fenoterol). These products have active registrations in the US (FDA), EU (EMA), Japan (PMDA), and many other markets. The absence from the Indian regulatory record represents a regulatory filing opportunity supported by a strong international evidence base.

Safety Considerations

Drug Interactions: 106 interactions identified in total. The large majority are moderate-level interactions with other anticholinergic or cholinergic-modulating agents, where the primary concern is additive anticholinergic burden (dry mouth, urinary retention, constipation, blurred vision, tachycardia). Key interactions include:

Interacting Drug	Level	Mechanism / Concern
Hyoscyamine	Moderate	Additive anticholinergic effects
Atropine	Moderate	Additive anticholinergic effects
Glycopyrronium	Moderate	Additive anticholinergic effects (same drug class)
Scopolamine	Moderate	Additive anticholinergic effects
Trospium	Moderate	Additive anticholinergic effects
Aclidinium	Moderate	Additive anticholinergic effects (same drug class)
Promethazine	Moderate	Additive anticholinergic + CNS sedative effects
Chlorpheniramine	Moderate	Additive anticholinergic effects via H1-antihistamine activity

Note: One case report (PMID 8449120) documents severe anaphylaxis following ipratropium inhalation, suspected to be related to the benzalkonium chloride preservative rather than ipratropium itself. Formulations intended for use in patients with known preservative sensitivity should be preservative-free.

Formal package-insert warnings and contraindications for the Indian market are not available from current regulatory records. Please refer to the Boehringer Ingelheim Atrovent® Summary of Product Characteristics (SmPC) for complete safety information before clinical or regulatory use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Ipratropium is one of the most extensively studied inhaled bronchodilators in the world, with a body of evidence that includes multiple completed Phase 3 RCTs, two Cochrane systematic reviews, and decades of post-marketing surveillance across large COPD cohorts. The TxGNN score of 99.97% reflects this depth of evidence. The primary barrier to market entry in India is the absence of a CDSCO registration — not a lack of clinical evidence.

To proceed, the following is needed:

CDSCO regulatory filing: Submit a marketing authorization application in India referencing existing global approvals (US FDA NDA, EMA MA) under the abridged or hybrid pathway
Local bridging data: Assess whether Indian patient population PK/safety bridging data is required or can be waived given the global approval package
Safety document review: Obtain and review the complete Atrovent® SmPC / USPI for warnings, contraindications, and special populations (glaucoma, BPH, pregnancy)
MOA documentation: Retrieve full mechanism of action from DrugBank (DB00332) to complete the regulatory dossier
Post-marketing pharmacovigilance plan: Establish a proactive safety monitoring protocol for the Indian market, with particular attention to preservative-related hypersensitivity
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.